Jeffrey Lennox

Identification of rare HIV-1-infected patients with extreme CD4+ T cell decline despite ART-mediated viral suppression.

S. Anzick, C. Martens, J. Brophy, 2019, JCI Insight.

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial

C. del Rio, L. Lam, C. Libertin, 2021, The Lancet Respiratory Medicine.

Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with HIV.

M. Lederman, C. Flexner, C. del Rio, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Predictors of success with highly active antiretroviral therapy in an antiretroviral-naive urban population.

Dominique L. Cosco, C. del Rio, Elisa Zaragoza-Macias, 2007, AIDS research and human retroviruses.

Pharmacokinetics of Ruxolitinib in HIV Suppressed Individuals on Antiretroviral Agent Therapy from the ACTG A5336 Study

M. Lederman, C. Flexner, C. del Rio, 2021, Journal of clinical pharmacology.

Effect of Immune-Modulatory Interventions on Asymptomatic Cytomegalovirus Shedding during Suppressive Antiretroviral Therapy.

M. Lederman, R. Bosch, S. Gianella, 2023, The Journal of infectious diseases.

Identification of rare HIV-1-infected patients with extreme CD4+ T cell decline despite ART-mediated viral suppression.

S. Anzick, C. Martens, J. Brophy, 2019, JCI insight.